Global Next Generation Antibody Therapeutics Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Antibody Drug Conjugates (ADCs)
  • 1.4.3 Bispecific Antibodies (BsAbs)
  • 1.4.4 Fc Engineered Antibodies
  • 1.4.5 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
  • 1.4.6 Biosimilar Antibody (Ab) Products
• 1.5 Market by Application
  • 1.5.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Next Generation Antibody Therapeutics Market Perspective (2015-2026)
• 2.2 Global Next Generation Antibody Therapeutics Growth Trends by Regions
  • 2.2.1 Next Generation Antibody Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Next Generation Antibody Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Next Generation Antibody Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Next Generation Antibody Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Next Generation Antibody Therapeutics Players by Market Size
  • 3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Next Generation Antibody Therapeutics Market Concentration Ratio
  • 3.2.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2019
• 3.3 Next Generation Antibody Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Next Generation Antibody Therapeutics Product Solution and Service
• 3.5 Date of Enter into Next Generation Antibody Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Next Generation Antibody Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Next Generation Antibody Therapeutics Market Size (2015-2020)
• 6.2 Next Generation Antibody Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Next Generation Antibody Therapeutics Market Size (2015-2020)
• 7.2 Next Generation Antibody Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Next Generation Antibody Therapeutics Market Size (2015-2020)
• 8.2 Next Generation Antibody Therapeutics Key Players in China (2019-2020)
• 8.3 China Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 8.4 China Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Next Generation Antibody Therapeutics Market Size (2015-2020)
• 9.2 Next Generation Antibody Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Next Generation Antibody Therapeutics Market Size (2015-2020)
• 10.2 Next Generation Antibody Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Next Generation Antibody Therapeutics Market Size (2015-2020)
• 11.2 Next Generation Antibody Therapeutics Key Players in India (2019-2020)
• 11.3 India Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 11.4 India Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Next Generation Antibody Therapeutics Market Size (2015-2020)
• 12.2 Next Generation Antibody Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Next Generation Antibody Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Next Generation Antibody Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Pfizer
  • 13.1.1 Pfizer Company Details
  • 13.1.2 Pfizer Business Overview
  • 13.1.3 Pfizer Next Generation Antibody Therapeutics Introduction
  • 13.1.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2015-2020))
  • 13.1.5 Pfizer Recent Development
• 13.2 Roche
  • 13.2.1 Roche Company Details
  • 13.2.2 Roche Business Overview
  • 13.2.3 Roche Next Generation Antibody Therapeutics Introduction
  • 13.2.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.2.5 Roche Recent Development
• 13.3 Bristol-Myers Squibb
  • 13.3.1 Bristol-Myers Squibb Company Details
  • 13.3.2 Bristol-Myers Squibb Business Overview
  • 13.3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Introduction
  • 13.3.4 Bristol-Myers Squibb Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.3.5 Bristol-Myers Squibb Recent Development
• 13.4 Amgen
  • 13.4.1 Amgen Company Details
  • 13.4.2 Amgen Business Overview
  • 13.4.3 Amgen Next Generation Antibody Therapeutics Introduction
  • 13.4.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.4.5 Amgen Recent Development
• 13.5 AstraZeneca
  • 13.5.1 AstraZeneca Company Details
  • 13.5.2 AstraZeneca Business Overview
  • 13.5.3 AstraZeneca Next Generation Antibody Therapeutics Introduction
  • 13.5.4 AstraZeneca Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.5.5 AstraZeneca Recent Development
• 13.6 Bayer
  • 13.6.1 Bayer Company Details
  • 13.6.2 Bayer Business Overview
  • 13.6.3 Bayer Next Generation Antibody Therapeutics Introduction
  • 13.6.4 Bayer Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.6.5 Bayer Recent Development
• 13.7 Takeda Pharmaceuticals
  • 13.7.1 Takeda Pharmaceuticals Company Details
  • 13.7.2 Takeda Pharmaceuticals Business Overview
  • 13.7.3 Takeda Pharmaceuticals Next Generation Antibody Therapeutics Introduction
  • 13.7.4 Takeda Pharmaceuticals Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.7.5 Takeda Pharmaceuticals Recent Development
• 13.8 Biogen
  • 13.8.1 Biogen Company Details
  • 13.8.2 Biogen Business Overview
  • 13.8.3 Biogen Next Generation Antibody Therapeutics Introduction
  • 13.8.4 Biogen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.8.5 Biogen Recent Development
• 13.9 Seattle Genetics
  • 13.9.1 Seattle Genetics Company Details
  • 13.9.2 Seattle Genetics Business Overview
  • 13.9.3 Seattle Genetics Next Generation Antibody Therapeutics Introduction
  • 13.9.4 Seattle Genetics Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.9.5 Seattle Genetics Recent Development
• 13.10 ImmunoGen
  • 13.10.1 ImmunoGen Company Details
  • 13.10.2 ImmunoGen Business Overview
  • 13.10.3 ImmunoGen Next Generation Antibody Therapeutics Introduction
  • 13.10.4 ImmunoGen Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 13.10.5 ImmunoGen Recent Development
• 13.11 Kyowa Hakko Kirin
  • 10.11.1 Kyowa Hakko Kirin Company Details
  • 10.11.2 Kyowa Hakko Kirin Business Overview
  • 10.11.3 Kyowa Hakko Kirin Next Generation Antibody Therapeutics Introduction
  • 10.11.4 Kyowa Hakko Kirin Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 10.11.5 Kyowa Hakko Kirin Recent Development
• 13.12 Xencor
  • 10.12.1 Xencor Company Details
  • 10.12.2 Xencor Business Overview
  • 10.12.3 Xencor Next Generation Antibody Therapeutics Introduction
  • 10.12.4 Xencor Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 10.12.5 Xencor Recent Development
• 13.13 Dyax Corp
  • 10.13.1 Dyax Corp Company Details
  • 10.13.2 Dyax Corp Business Overview
  • 10.13.3 Dyax Corp Next Generation Antibody Therapeutics Introduction
  • 10.13.4 Dyax Corp Revenue in Next Generation Antibody Therapeutics Business (2015-2020)
  • 10.13.5 Dyax Corp Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer